journal article·2026-01

Trojan horse natural killer cells enhance targeted drug delivery and boost memory T cell-mediated immune responses in triple-negative breast cancer

Liya Wu, Hua Yao, Yubo Wang, Haiou Liu, Huiying Lv, Dan Jiao, Jinlan Jiang

Acta Biomaterialia· Volume 210
Publisher page

Abstract

Natural killer (NK) cell-based cancer therapy is a key innovation in immunotherapy. However, current research on drug delivery systems (DDSs) mediated by NK "dead cells" remains limited. Accordingly, we developed an innovative method to obtain dead NK cells as drug carriers using rapid vitrification freezing and slow-programmed thawing. Freeze-thawed NK cells (FTKs) showed enhanced tumor-targeting ability by upregulating the expression of C-X-C motif chemokine receptor 3 and integrin beta 2. Therefore, FTKs function as Trojan horse-like carriers, enabling efficient delivery of toxic chemotherapeutic agents. In addition, FTKs were also found to stimulate the maturation of dendritic cells (DCs) via the release of danger-associated molecular patterns. In conjunction with chemotherapy, this strategy can synergistically leverage the immunomodulatory properties of chemotherapeutic drugs to increase immunogenic cell death, mitigate immunosuppression within the tumor microenvironment, and slow the progression of triple-negative breast cancer (TNBC). Using a metastatic TNBC mouse model, this strategy enhanced the immunological effect of a programmed cell death protein 1 inhibitor by re-invigorating cytotoxic T lymphocytes and promoting the reacquisition of memory T-cell responses. Hence, we propose an NK "dead cell"-based enhanced target delivery system that can be rapidly manufactured for clinical use, thus providing insights into innovative immunotherapy drug delivery strategies. STATEMENT OF SIGNIFICANCE: Triple-negative breast cancer is a highly aggressive subtype of breast cancer, for which chemotherapy is the primary treatment modality. However, conventional chemotherapy is often limited by insufficient target specificity, leading to systemic toxicity. In this study, we developed a drug delivery platform based on natural killer (NK) cells. By processing cells via rapid vitrification freezing and slow-programmed thawing, we obtained freeze-thawed NK cells (FTKs) characterized by an intact membrane architecture and enhanced tumor-targeting capacity. In addition, FTKs were found to promote dendritic cell maturation and had a high drug-loading capacity. In conjunction with chemotherapy, this strategy enhanced the immunological effect of a programmed cell death protein 1 inhibitor by re-invigorating cytotoxic T lymphocytes and promoting the reacquisition of memory T-cell responses.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immune Cell Function and Interaction · CAR-T cell therapy research · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (63)

Show source-provided references
1. Advances in systemic therapies for triple negative breast cancer10.1136/bmj-2022-071674 ↗
2. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease10.1038/nrclinonc.2016.66 ↗
3. The future of immune checkpoint therapy10.1126/science.aaa8172 ↗
4. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors10.1038/s41571-020-0413-z ↗
5. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy10.1038/nature19330 ↗
6. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade10.1126/science.aaf2807 ↗
7. Nanoparticulate carriers: an emerging tool for breast cancer therapy10.3109/1061186X.2014.958844 ↗
8. Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—Challenges and opportunities10.3390/nano8060361 ↗
9. Bioactive nanotherapeutic trends to combat triple negative breast cancer
10. Cryo-shocked cancer cells for targeted drug delivery and vaccination10.1126/sciadv.abc3013 ↗
11. Walking dead tumor cells for targeted drug delivery against lung metastasis of triple-negative breast cancer10.1002/adma.202205462 ↗
12. Harnessing the formation of natural killer–Tumor cell immunological synapses for enhanced therapeutic effect in solid tumors
13. Exploring the NK cell platform for cancer immunotherapy10.1038/s41571-020-0426-7 ↗
14. Enhanced cytotoxic function of natural killer and CD3+CD56+ cells in cord blood after culture10.1016/j.bbmt.2014.10.014 ↗
15. Immunogenic cell stress and death10.1038/s41590-022-01132-2 ↗
16. Trial Watch: immunogenic cell death inducers for anticancer chemotherapy10.1080/2162402X.2015.1008866 ↗
17. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming10.1111/imr.13281 ↗
18. Oncology meets immunology: the cancer-immunity cycle10.1016/j.immuni.2013.07.012 ↗
19. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation10.1016/j.humimm.2011.12.015 ↗
20. Dysregulation of Chemokine/Chemokine receptor axes and NK cell tissue localization during diseases10.3389/fimmu.2016.00402 ↗
21. Hepatic lipid remodeling in cold exposure uncovers direct regulation of bis(monoacylglycero)phosphate lipids by phospholipase A2 group XV10.1016/j.cmet.2025.04.015 ↗
22. Cold temperature extends longevity and prevents disease-related protein aggregation through PA28γ-induced proteasomes10.1038/s43587-023-00383-4 ↗
23. Endoplasmic reticulum stress in cancer progression: a comprehensive review of its role and mechanisms10.7150/ijms.120874 ↗
24. Integrated transcriptomics and metabolomics confirms the oxidative stress mechanism of hypothermia-induced neuronal necroptosis10.1186/s11658-025-00772-0 ↗
25. Chemical approaches to cryopreservation10.1038/s41570-022-00407-4 ↗
26. Mitoxantrone as photothermal agents for ultrasound/fluorescence imaging-guided chemo-phototherapy enhanced by intratumoral H2O2-induced CO10.1016/j.biomaterials.2020.120111 ↗
27. Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR10.1186/s12943-024-02150-4 ↗
28. Differential expression of CD49a and CD49b determines localization and function of tumor-infiltrating CD8+ T cells10.1158/2326-6066.CIR-20-0427 ↗
29. The ways of actin: why tunneling nanotubes are unique cell protrusions10.1016/j.tcb.2020.11.008 ↗
30. Tyrosine phosphorylation of the myosin regulatory light chain controls non-muscle myosin II assembly and function in migrating cells10.1016/j.cub.2020.04.057 ↗
31. Cell death induced by cytotoxic CD8+ T cells is immunogenic and primes caspase-3–dependent spread immunity against endogenous tumor antigens
32. Immunogenic cell death, DAMPs and prothymosin α as a putative anticancer immune response biomarker10.3390/cells11091415 ↗
33. Dying cells actively regulate adaptive immune responses10.1038/nri.2017.9 ↗
34. Resistance mechanisms to Immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors10.1016/j.immuni.2016.06.001 ↗
35. Regulatory T (Treg) cells in cancer: can treg cells be a new therapeutic target?10.1111/cas.14069 ↗
36. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets10.1016/j.semcancer.2019.08.012 ↗
37. Breast cancer treatment: a review10.1001/jama.2018.19323 ↗
38. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy10.1038/nri.2017.49 ↗
39. The role of CXCR3 and its ligands in cancer
40. Cxcr3 promotes protection from colorectal cancer liver metastasis by driving NK cell infiltration and plasticity10.1172/JCI184036 ↗
41. Nano-delivery systems focused on tumor microenvironment regulation and biomimetic strategies for treatment of breast cancer metastasis10.1016/j.jconrel.2021.03.039 ↗
42. Preparation and application of pH-responsive drug delivery systems10.1016/j.jconrel.2022.05.056 ↗
43. Charge-reversible nanoparticles: advanced delivery systems for therapy and diagnosis10.1002/smll.202304713 ↗
44. Drugging the efferocytosis process: concepts and opportunities10.1038/s41573-022-00470-y ↗
45. An apoptotic ‘eat me’ Signal: phosphatidylserine exposure10.1016/j.tcb.2015.08.003 ↗
46. IFN-γ induces high mobility group box 1 protein release partly through a TNF-dependent mechanism10.4049/jimmunol.170.7.3890 ↗
47. HMGB1 in health and disease10.1016/j.mam.2014.05.001 ↗
48. Efficient T cell migration and activation require L-plastin10.3389/fimmu.2022.916137 ↗
49. Antigen presentation in cancer — Mechanisms and clinical implications for immunotherapy10.1038/s41571-023-00789-4 ↗
50. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs10.1038/s41571-021-00565-2 ↗
51. Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer10.18632/oncotarget.22110 ↗
52. Influence of tumour micro-environment heterogeneity on therapeutic response10.1038/nature12626 ↗
53. Primary, adaptive, and acquired resistance to cancer immunotherapy10.1016/j.cell.2017.01.017 ↗
54. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging10.1016/j.cell.2018.08.039 ↗
55. Resistance to PD1/PDL1 checkpoint inhibition10.1016/j.ctrv.2016.11.007 ↗
56. The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation10.1038/nri3173 ↗
57. Nanomaterial-based repurposing of macrophage metabolism and its applications
58. Biomimetic targeted self-adaptive nanodrug for inflammation optimization and AT2 cell modulation in precise ARDS therapy10.1126/sciadv.adw5133 ↗
59. Loading of enzymatic cargos into extracellular vesicles derived from lung cancer cells10.2147/IJN.S528193 ↗
60. Potentiating cancer vaccination by adjuvant-loaded cryo-shocked tumor cells10.1016/j.biomaterials.2023.122319 ↗
61. Cryo-trojan mesenchymal stem cells as non-living tumor-homing supercarriers for enhanced drug delivery and immune activation in prostate cancer
62. Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances10.1186/s13046-025-03503-7 ↗
63. The role of NK cells in cancer immunotherapy: mechanisms, evasion strategies, and therapeutic advances10.3390/biomedicines13040857 ↗